However, due to the poor long-term retention of PSMA-targeting radiopharmaceuticals, these non-prostate tumors can be readily discerned by poor retention of LuPSMA in 24-hour post-therapeutic single-photon emission computed tomography/CT (SPECT/CT) imaging [4]. Here, FOLH1 is linked to prostate neoplasm.